Clinical trial on ibandronate in patients with tumor-associated hypercalcemia.
- Author:
Tao WANG
1
;
San-tai SONG
;
Ze-fei JIANG
;
Shou-geng BIAN
;
Ya-jie WANG
;
Li-qing LI
;
Jun ZHU
Author Information
- Publication Type:Clinical Trial
- MeSH: Bone Neoplasms; complications; secretion; Breast Neoplasms; complications; pathology; Calcium; blood; Diphosphonates; administration & dosage; therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; chemically induced; Humans; Hypercalcemia; blood; drug therapy; etiology; Lung Neoplasms; complications; pathology; Male; Middle Aged; Multiple Myeloma; complications; Phosphorus; blood; Pruritus; chemically induced
- From: Chinese Journal of Oncology 2004;26(12):739-741
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEIbandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.
METHODSAn open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.
RESULTSThere was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.
CONCLUSIONIbandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.
